You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華-B(09969.HK)公佈中期業績 收益增加53.5% 研發開支增加至3.58億元

格隆匯8月29日丨諾誠健華-B(09969.HK)公吿,2023年中期,公司收益增加53.5%至人民幣377.5百萬元,主要由於奧布替尼的銷量持續快速增長所致。奧布替尼的銷售額由上年同期的人民幣217.0百萬元增加47.8%至期間的人民幣320.7百萬元。

公司的研發開支由上年同期的人民幣273.5百萬元增加至期間的人民幣358.1百萬元,主要由於持續推進研發過程而導致臨牀前、臨牀試驗開支及研發團隊的人才儲備成本增加。

於2023年上半年,公司繼續推進公司強大的在研產品線,包括13種寶貴的藥物(其中有2款已商業化的產品)、30多項處於不同臨牀階段的正在進行的全球試驗,以及在研究及開發、製造、商業化及協作方面有一貫強大執行力和明確增長戰略的業務運營。

此外,公司正在就2025年後即將推出的新產品規劃第三期建設。截至本公吿日期,公司已完成第二期建設,新增30,000平方米的生產面積,以支持公司不斷增長的在研藥物及持續業務擴張。

公司預計,隨着公司擴大全球研發產品線、推進商業化和提升生產能力,隨後數年將是公司的轉型期。為實現公司成為全球生物製藥領導者併為全球患者開發和提供創新療法的願景,公司將專注於以下幾個方面:建立在血液腫瘤領域領先的專營權;在自身免疫性疾病中開發B細胞及T細胞通路;打造中國乃至全球用於實體瘤治療的具競爭力的藥物組合;繼續通過自主研發及業務拓展提升公司的在研產品線;通過內部和外部的努力建立生物藥物的自主研發能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account